FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 339 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Answers to Your Questions About Sunscreen Ingredients April 21, 2022 EMA Recommends Granting a Marketing Authorisation for Retifanlimab February 26, 2024 Shelter Puppies Got A Private Tour Of The Georgia Aquarium March 31, 2020 Man Gets His First Haircut In 15 Years To Join The... August 21, 2019 Load more HOT NEWS Liquid Biopsies on the Horizon for Children with Solid Cancers Could Bacteria Help Find Cancer? NCI Launches New Resource for Specimens and Data from Cancer Clinical... How People With Cancer Can Benefit From Online Therapy
